HC Wainwright Begins Coverage on vTv Therapeutics (NASDAQ:VTVT)

HC Wainwright initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research report report published on Wednesday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $36.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for vTv Therapeutics’ Q1 2025 earnings at ($0.73) EPS, Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($3.97) EPS, FY2026 earnings at ($3.57) EPS, FY2027 earnings at ($3.94) EPS, FY2028 earnings at ($3.67) EPS and FY2029 earnings at ($2.70) EPS.

Separately, StockNews.com initiated coverage on vTv Therapeutics in a research report on Thursday, March 27th. They set a “sell” rating for the company.

vTv Therapeutics Stock Down 4.2 %

NASDAQ VTVT traded down $0.79 during trading hours on Wednesday, hitting $17.75. The company’s stock had a trading volume of 1,584 shares, compared to its average volume of 22,959. The stock has a fifty day moving average of $17.83 and a 200 day moving average of $15.69. vTv Therapeutics has a twelve month low of $12.12 and a twelve month high of $29.19. The firm has a market capitalization of $56.61 million, a P/E ratio of -3.92 and a beta of 0.81.

vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Thursday, March 20th. The biotechnology company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.32. The firm had revenue of $0.02 million during the quarter.

Hedge Funds Weigh In On vTv Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC bought a new stake in shares of vTv Therapeutics in the 3rd quarter valued at about $2,402,000. JPMorgan Chase & Co. bought a new stake in vTv Therapeutics in the 4th quarter valued at $25,000. Finally, Geode Capital Management LLC boosted its stake in shares of vTv Therapeutics by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock valued at $158,000 after buying an additional 1,327 shares during the period. 17.51% of the stock is owned by institutional investors.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.